Impact of Clostridioides difficile Therapy on Nosocomial Acquisition of Vancomycin-Resistant Enterococci

Vancomycin is frequently used for the treatment of C. difficile infections (CDI). There are concerns that this might increase the risk of selecting vancomycin resistant enterococci (VRE). Here, we evaluated whether there is an increased risk of VRE acquisition following vancomycin for CDI specific t...

Descripción completa

Detalles Bibliográficos
Autores principales: Correa-Martínez, Carlos L., Hagemeier, Niklas C. J., Froböse, Neele J., Kampmeier, Stefanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8625989/
https://www.ncbi.nlm.nih.gov/pubmed/34832848
http://dx.doi.org/10.3390/ph14111066

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8625989/
https://www.ncbi.nlm.nih.gov/pubmed/34832848
http://dx.doi.org/10.3390/ph14111066

Ejemplares similares